Though 2009 has passed (finally), the year saw a number of regulatory filings - Danbury, Conn.-based Biodel Inc.'s new drug application for Viaject injectable insulin made it just under the wire with a Dec. 30 submission - that make for some much-awaited action dates in the first half of 2010. (BioWorld Today) Read More
